Repositioning Candidate Details
| Candidate ID: | R0784 |
| Source ID: | DB05407 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | TBC-3711 |
| Synonyms: | -- |
| Molecular Formula: | C20H21N3O5S2 |
| SMILES: | CC(=O)C1=C(NC(=O)C2=C(C=CS2)S(=O)(=O)NC2=C(C)C(C)=NO2)C(C)=CC(C)=C1 |
| Structure: |
|
| DrugBank Description: | TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals. |
| CAS Number: | 349453-49-2 |
| Molecular Weight: | 447.52 |
| DrugBank Indication: | Investigated for use/treatment in congestive heart failure, hypertension, and pulmonary hypertension. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | TBC3711 is a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. It is a next-generation endothelin A antagonist which possesses high oral bioavailability and is more selective and potent than THELIN(tm) (sitaxsentan sodium) Encysive's oral treatment for pulmonary arterial hypertension. TBC3711 is greater than 100,000-fold selective in the targeting of the endothelin A receptor versus the endothelin B receptor. |
| Targets: | Endothelin-1 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |